MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by THUT, P. D.
Right arrow Articles by LINDELL, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by THUT, P. D.
Right arrow Articles by LINDELL, T. J.

Molecular Pharmacology, Vol 10, 146-154, Copyright © 1974 by the American Society for Pharmacology and Experimental Therapeutics

agr-Amanitin Inhibition of Mouse Brain Form II Ribonucleic Acid Polymerase and Passive Avoidance Retention

PAUL D. THUT 1 and THOMAS J. LINDELL 1

1 Department of Pharmacology, Arizona Medical Center, University of Arizona, Tucson, Arizona 85724

Injection of agr-amanitin into a cerebral ventricle reduced the ability of male mice to retain a passive avoidance response without affecting spontaneous locomotor activity or performance of a previously learned task. agr-Amanitin inhibited the brain form II DNA-dependent RNA polymerase in a dose-dependent manner up to 10 µg, at which dose a maximum of 98% inhibition was observed as determined by assay of brain nuclei at the time of training. The effect observed on passive avoidance retention is only seen at maximal (98%) inhibition. Furthermore, the inhibition of brain form II polymerase is transient, indicating that agr-amanitin is effective in vivo only when virtually 100% inhibition of this enzyme is attained. The liver form II polymerase was also inhibited after cerebroventricular injection, indicating that a significant amount of the agr-amanitin reached peripheral circulation. A 50% inhibition of liver form II polymerase was measured within 15 min. However, intraperitoneal injection of 10 µg of agr-amanitin did not produce significant inhibition of brain form II polymerase, and retention of a passive avoidance response was not affected.

Note:
ACKNOWLEDGMENTS We thank Professor T. Wieland for a generous gift of agr-amanitin. The expert technical assistance of Sandra Burt , Royal Ellinger, Tony O'Malley, James Warren, Colleen Bentley, and Janet Neuberg is gratefully acknowledged. We thank Dr. Rubin Bressler for continued interest and support.

Submitted on May 11, 1973




This article has been cited by other articles:


Home page
Physiol. Rev.Home page
C. M. Alberini
Transcription Factors in Long-Term Memory and Synaptic Plasticity
Physiol Rev, January 1, 2009; 89(1): 121 - 145.
[Abstract] [Full Text] [PDF]


Home page
Learn. Mem.Home page
S. Duvarci, K. Nader, and J. E. LeDoux
De novo mRNA synthesis is required for both consolidation and reconsolidation of fear memories in the amygdala
Learn. Mem., October 2, 2008; 15(10): 747 - 755.
[Abstract] [Full Text] [PDF]


Home page
Learn. Mem.Home page
H. J. Ahn, C. M. Hernandez, J. M. Levenson, F. D. Lubin, H.-C. Liou, and J. D. Sweatt
c-Rel, an NF-{kappa}B family transcription factor, is required for hippocampal long-term synaptic plasticity and memory formation
Learn. Mem., July 11, 2008; 15(7): 539 - 549.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1974 by the American Society for Pharmacology and Experimental Therapeutics